<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105722">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01676662</url>
  </required_header>
  <id_info>
    <org_study_id>CD 1004</org_study_id>
    <nct_id>NCT01676662</nct_id>
  </id_info>
  <brief_title>Solace European Confirmatory Trial</brief_title>
  <acronym>SOLECT</acronym>
  <official_title>An Evaluation of the Solace Bladder Control System in the Treatment of Female Subjects With Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solace Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solace Therapeutics, Inc.</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Solace European Confirmatory (SOLECT) Trial is designed to determine whether the Solace
      Bladder Control System is safe and effective for the treatment of Stress Urinary
      Incontinence (SUI) in adult females.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subject will undergo treatment with the Solace Bladder Control System or a sham procedure,
      with the results being compared at 3 months.

      All patients undergoing sham treatment are treated at 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in quality of life as assessed by pad weight tests assessments and questionnaires</measure>
    <time_frame>3 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of increases in pad weight test and patient reported outcomes on questionnaires.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related adverse events</measure>
    <time_frame>3 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Site-reported adverse events designated as related to the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of treatment-related adverse events</measure>
    <time_frame>3 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Site-reported adverse events designated as related to the treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of all adverse events</measure>
    <time_frame>36 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Rate of incidence of all adverse events for all patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Improvement in quality of life in all patients assessed with pad weight tests and questionnaires</measure>
    <time_frame>36 Months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Severity of all adverse events</measure>
    <time_frame>36 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Severity of all adverse events for all patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Treatment on Day 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are treated with the Solace Bladder Control System upon entry into the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Treatment on Day 0</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients who undergo a sham procedure upon entry into the trial, with treatment with the Solace Bladder Control System at 3 months after the sham procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solace Bladder Control System</intervention_name>
    <description>Subjects may undergo treatment every 12 months until study completion.</description>
    <arm_group_label>Treatment on Day 0</arm_group_label>
    <arm_group_label>Sham Treatment on Day 0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solace Sham Treatment</intervention_name>
    <description>Sham procedure that resembles treatment with the Solace Bladder Control System</description>
    <arm_group_label>Sham Treatment on Day 0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female 18 years of age or older with stress urinary incontinence (SUI)

          -  Experienced SUI for at least 12 months and attempted and failed prior noninvasive
             treatment

          -  Willing to undergo cystoscopic procedures required and 36 month follow-up

          -  On stable medication for a minimum of 3 months

          -  Free of local genital skin infection

          -  Positive Pad Weight Test

          -  Free of impassable urethral strictures, trauma or necrosis

        Exclusion Criteria (must answer NO):

          -  Pregnant or planning to become pregnant during the study period

          -  Non-ambulatory or bedridden or physically unable to complete test exercises

          -  Morbidly obese (defined as BMI ≥ 40 kg/m2)

          -  Bladder infection (including bladder inflammation or edema) or UTI within 3 months

          -  History of recurrent urinary tract infections

          -  Prior surgical procedure for incontinence within the past 6 months

          -  Is taking medications for urinary incontinence other than anticholinergics

          -  History of kidney stones

          -  Has a prosthetic heart valve

          -  Unable to tolerate any form of antibiotic

          -  Taking anticoagulation therapy, other than aspirin

          -  Has urinary incontinence due to Intrinsic Sphincter Deficiency (ISD)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Tommaselli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Antwerp Hospital (Universitair Ziekenhuis Antwerpen)</name>
      <address>
        <city>Antwerp</city>
        <state>Edegem</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>B-1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Naples (Università Degli Studi Di Napoli &quot;Federico II&quot; )</name>
      <address>
        <city>Naples (Napoli)</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Campus Bio-medico di Roma</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>August 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Incontinence</keyword>
  <keyword>Urinary Incontinence, Stress</keyword>
  <keyword>Urination Disorders</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>Urological Manifestations</keyword>
  <keyword>Signs and Symptoms</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
